Maze Therapeutics Inc. (MAZE) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Maze Therapeutics Inc.

    NASDAQ: MAZE · Real-Time Price · USD
    14.97
    -0.91 (-5.73%)
    At close: Sep 08, 2025, 3:59 PM
    14.55
    -2.81%
    After-hours: Sep 08, 2025, 06:40 PM EDT

    Maze Therapeutics Income Statement

    Financials in USD. Fiscal year is undefined.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022
    Revenue
    		 167.5M n/a n/a
    Cost of Revenue
    		 3.3M 4.09M 3.82M
    Gross Profit
    		 167.5M -4.09M -3.82M
    Operating Income
    		 57.59M -98.55M -111.03M
    Interest Income
    		 4.65M 1.97M 2.03M
    Pretax Income
    		 53.4M -100.42M -114.94M
    Net Income
    		 52.23M -100.42M -114.94M
    Selling & General & Admin
    		 26.42M 24.61M 22.83M
    Research & Development
    		 83.5M 73.94M 88.19M
    Other Expenses
    		 n/a n/a n/a
    Operating Expenses
    		 109.91M 98.55M 111.03M
    Interest Expense
    		 n/a n/a n/a
    Selling & Marketing Expenses
    		 n/a n/a n/a
    Cost & Expenses
    		 109.91M 98.55M 111.03M
    Income Tax Expense
    		 1.17M n/a n/a
    Shares Outstanding (Basic)
    		 43.8M 43.78M 43.78M
    Shares Outstanding (Diluted)
    		 43.8M 43.78M 43.78M
    EPS (Basic)
    		 0.08 -2.29 -2.63
    EPS (Diluted)
    		 0.08 -2.29 -2.63
    EBITDA
    		 60.88M -94.46M -107.21M
    EBIT
    		 57.59M -98.55M -111.03M
    Depreciation & Amortization
    		 3.3M 4.09M 3.82M

    Add to Watchlist